Sorry, you need to enable JavaScript to visit this website.

Skip to main content

Search

Our Leadership

Meet Our Leadership Team

Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in Oncology, Immunology, NeuroscienceInfectious Diseases & Vaccines, Cardiovascular & Metabolism and Pulmonary Hypertension. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. We recognize the impact of serious conditions on people's lives, and we aim to empower people through disease awareness, education and access to quality care.

As part of the Johnson & Johnson Family of Companies, the world's most comprehensive and broadly based manufacturer of healthcare products, we believe that we have an opportunity and an obligation to make a significant positive impact in the world by addressing the most serious unmet medical needs of our time.

Here is our leadership team that guides Janssen.

JOAQUIN DUATO

EXECUTIVE VICE PRESIDENT AND WORLDWIDE CHAIRMAN, PHARMACEUTICALS,
JOHNSON & JOHNSON

Joaquin Duato is a globally experienced, values-driven pharmaceutical leader and currently the Executive Vice President and Worldwide Chairman, Pharmaceuticals, at Johnson & Johnson, the world’s premiere healthcare company and fifth-largest pharmaceutical business. He is a respected industry leader and is the Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). In recognition of his thought leadership, he was recently appointed to the Board of the CEO Roundtable on Cancer.

Joaquin played an instrumental role in leading the dramatic turnaround of the Johnson & Johnson pharmaceuticals business. A 27-year veteran of the Company, Joaquin was named Company Group Chairman of the Americas in 2009.  He then continued leading the global transformation upon his appointment as Worldwide Chairman in 2011.  With a focus on creating innovative commercial solutions and processes to support the Company’s cutting-edge medicines, he inspires employees to focus on transforming the lives of patients.  The results are clear: with 16 new products launched since 2009 and 10 potential billion-dollar medicines expected to be filed before 2019, the Johnson & Johnson pharmaceuticals sector is poised to remain one of the fastest growing Top Ten pharmaceutical companies globally.

As a dual citizen of Spain and the United States, Joaquin brings a unique international perspective to his work.  With a career spanning three countries and two regions, he appreciates the value of diversity of experiences and opinions.  He brings this to bear externally as an active Board member of the U.S. Spain Council and internally as the Executive Sponsor of the African American Leadership Council.  His passion for nurturing a culture of diversity was recognized in 2015 when he was named one of America’s Top 10 Hispanic Business Leaders by Hispanic Career World.

Joaquin also has a passion for learning, with an undergraduate degree in economics and business, a Master’s in Business Administration (MBA) from ESADE Business School in Barcelona, Spain, and a Masters of International Management from Thunderbird in Phoenix, Arizona.  He is a champion of improving access to both health literacy and education more broadly through his role as Board Member of the international charity Save the Children.  He has served on the International Advisory Board of ESADE. In addition, he mentors MBA candidates at universities around the world and has spoken on leadership in the pharmaceutical industry at academic institutions including the Massachusetts Institute of Technology (MIT), Columbia Business School and The Wharton School.

Ultimately, he approaches every day with a clear sense of purpose and urgency, inspired by the words of Dr. Paul Janssen, “The patients are waiting.”

Joaquin Duato

Executive Vice President and Worldwide Chairman, Pharmaceuticals,
Johnson & Johnson

PAUL STOFFELS, M.D.

CHIEF SCIENTIFIC OFFICER, JOHNSON & JOHNSON

As Chief Scientific Officer, Johnson & Johnson, Paul Stoffels works with leaders across the organization to set the company-wide innovation agenda. He is a member of the Johnson & Johnson Executive Committee and chairs the Johnson & Johnson R&D Management Committee.

Paul spearheads the Johnson & Johnson innovation pipeline by leading teams across the pharmaceutical, medical devices and consumer segments to discover and develop transformational healthcare solutions. He also steers Johnson & Johnson’s global public health strategy to make innovative medicines and technologies accessible in resource-poor settings.

Paul’s visionary leadership was instrumental in the launch of Johnson & Johnson Innovation in 2013, which he now leads to fuel innovative science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry.

In addition, Paul has responsibility for safety of all products of the Johnson & Johnson Family of Companies worldwide.

Previously, in his role as Worldwide Chairman, Pharmaceuticals, Paul was responsible for advancing the therapeutic pipeline of Janssen Pharmaceutical Companies of Johnson & Johnson. Under his leadership, Janssen rejuvenated its therapeutic pipeline, launching multiple new medicines and bringing years of life and quality of life to people all over the world.

Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and as Chairman of Tibotec, and led the development of a number of breakthrough products for the treatment of HIV.

Paul studied medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.

Paul Stoffels, M.D.

Chief Scientific Officer,
Johnson & Johnson

PETE BATESKO

VICE PRESIDENT, GROUP FINANCE, PHARMACEUTICALS

Pete Batesko is Vice President, Group Finance for the Pharmaceuticals Group of Johnson & Johnson.  In this position, Pete reports directly to Johnson & Johnson’s Chief Financial Officer, Dominic Caruso, and provides finance leadership to the Pharmaceuticals Group, supporting Joaquin Duato and Paul Stoffels, as a member of the Group Operating Committee. He assumed this position on August 1, 2016.

Prior to taking this position, Pete served as Vice President, Group Finance and played a critical leadership role in the restructuring and transformation of our Medical Device Group.  Prior to this role, in June 2012, Pete was appointed Vice President, Group Finance for the DePuy Synthes Companies of Johnson & Johnson, where he managed all financial aspects of the Orthopaedic business worldwide and was a member of the Group Operating Committee.

From 2006 to 2012, Pete served as the Worldwide Vice President and Chief Financial Officer for DePuy Orthopaedics, Inc. In that role, he assisted with the acquisition of Synthes and the creation of the world’s most comprehensive orthopaedic and neurological company. From 2003-2006, Pete was the Vice President of Finance and Chief Financial Officer for Ortho Biotech Products, L.P. During that tenure, he oversaw all financial areas including health care compliance, process excellence and was part of the team that returned PROCRIT® to growth.

Pete has 35 years of Johnson & Johnson experience, beginning his career in 1981 as an auditor at headquarters in New Brunswick, New Jersey. From 1995 to 2003, he worked for Ortho-McNeil Pharmaceutical, Inc. as a controller. In that role, Pete led financial oversight of various groups including Business Development, Sales and Marketing.  During this time Pete was also a member of the team responsible for the acquisition of Centocor.

He earned his Bachelor of Science degree in Accounting from Villanova University, Villanova, Pennsylvania, and is a licensed certified Public Accountant (CPA) and Certified Management Accountant (CMA).

Pete Batesko

Vice President, Group Finance, Pharmaceuticals

COURTNEY L. BILLINGTON

VICE PRESIDENT, JANSSEN SUPPLY CHAIN

Courtney Billington is Vice President of Janssen Supply Chain (JSC) within the Johnson & Johnson Family of Companies. JSC is responsible for the global manufacturing and distribution of all biopharmaceutical brands. He assumed this role in April 2012.

In this role, Courtney is responsible for the leadership of more than 9,400 associates working in 26 pharmaceutical, biologic and chemical manufacturing sites around the world. He has nearly 23 years with the Johnson & Johnson Family of Companies, and spent the last 13 years within Pharmaceuticals. He also spent 10 years in the Medical Devices and Diagnostics business unit.

In his career, Courtney has held a variety of executive leadership positions such as: Vice President, Strategic Planning and Process Excellence; Vice President, Operations for North America; Vice President, Global Supply Chain; Vice President, Global Manufacturing & Technical Operations; Regional Marketing Manager; and New Technology Sales Representative.

Courtney began his career as Quartermaster Officer in the United States Army. After serving in a number of leadership positions with the 18th Airborne Corps at Fort Campbell, Kentucky, he retired after serving in Operation Desert Storm.

He is a member of the Executive Leadership Council, Cisco Manufacturing Advisory Board, Executive Council of the International Society of Pharmaceutical Engineering (ISPE) and the United Way of Somerset County Local Operating Board.

Courtney holds a Bachelor’s of Science degree in General Engineering Management from the United States Military Academy at West Point in New York.

Courtney L. Billington

Vice President, Janssen Supply Chain

ELIZABETH BLACKWOOD

VICE PRESIDENT AND CHIEF QUALITY OFFICER, PHARMACEUTICALS

Elizabeth Blackwood is Vice President, Chief Quality Officer, Pharmaceuticals. She is a member of the Pharmaceuticals Group Operating Committee (GOC) and the Johnson & Johnson Quality & Compliance Leadership Team. She assumed this role in January 2015.

In this role, Liz is responsible for setting quality strategy and leading the implementation of quality processes and systems to achieve world-class performance in the Pharmaceuticals sector.

Previously, Liz served as Vice President, Quality Systems & Strategy, where she led the development of a common set of Johnson & Johnson quality standards and the supporting Information Technology infrastructure. Liz’s guidance was critical to the successful deployment of these tools. Her purview also included Customer Logistics & Services Quality and Operations Readiness and Convergence.

Liz first joined Johnson & Johnson in 2000, and returned in 2012 after four years with GE Healthcare as Senior Vice President, Global Quality Assurance where she was responsible for establishing one global quality management system across more than 100 sites. Prior to joining GE Healthcare, she worked at LifeScan, Inc.; Ethicon Endo-Surgery, Inc.; Ethicon, Inc.; and Johnson & Johnson Corporate Quality & Compliance Services. Her last position at Johnson & Johnson before joining GE Healthcare was Worldwide Vice President, Quality, Regulatory and Medical Affairs, at LifeScan, Inc.

Liz holds an Associate of Science degree in manufacturing technology from Keene State College, Keene, New Hampshire, a Bachelor of Science degree in Mechanical Engineering from the University of Lowell, Lowell, Massachusetts, and a Master of Science degree in Management from Lesley College, Cambridge, Massachusetts. She also serves on the United States Food & Drug Administration Good Manufacturing Practices Advisory Committee and is a voting member of the International Organization for Standardization Technical Advisory Groups (ISO TAG) 176 Quality Systems Standards.

Elizabeth Blackwood

Vice President and Chief Quality Officer, Pharmaceuticals

LINDA FEDOW

GLOBAL LEAD, PHARMACEUTICALS COMMUNICATION & PUBLIC AFFAIRS

Linda Fedow is Global Lead, Pharmaceuticals Communication & Public Affairs. She assumed this position in May 2012.

In this role, Linda is responsible for building the equity and reputation of Janssen as a leading global pharmaceuticals business and has accountability for the internal and external communication teams supporting Janssen around the world. She is a member of the Pharmaceuticals Group Operating Committee (GOC) and the Corporate Communication Leadership Team.

Prior to assuming her current role, Linda served as Vice President, Communication & Public Affairs, the Americas, in the Pharmaceuticals Group. As a member of the North America Leadership Team, she was responsible for developing communication and public affairs strategies to support the commercial objectives of the Janssen businesses in the United States, Latin America and Canada.

Previously, Linda was Vice President, Group Communications for the Comprehensive Care Group and served on its Group Operating Committee. In that role, she had dual responsibility, also serving as the global communication leader for the Ortho-Clinical Diagnostics franchise.

Linda joined the Johnson & Johnson Family of Companies in 1997 from a major international public relations agency, where she was responsible for marketing communications and wellness management strategies for consumer, healthcare, and food and beverage products. During her career at Johnson & Johnson, she has had regional and global accountabilities for the communication function within a number of operating companies and franchises, including women's health, central nervous system, analgesia, biopharmaceuticals and internal medicine.

Linda holds Bachelor of Science and Master of Arts degrees in Biology from the City University of New York.

Linda Fedow

Global Lead, Pharmaceuticals Communication & Public Affairs

ROB FLETCHER, J.D.

GENERAL COUNSEL, PHARMACEUTICALS

Rob Fletcher is General Counsel, Pharmaceuticals and is responsible for legal matters relating to the Pharmaceuticals Group. In addition, the Legal group providing on-site support to the Johnson & Johnson Innovation Centers also reports into Rob. Rob also has oversight of the One J&J Southeast Asia Legal team. He assumed this position in January 2016.

Most recently Rob served as General Counsel, Medical Devices Group (including our Consumer Medical Technology businesses). During his tenure Rob has served as a trusted advisor to the Medical Devices leadership and businesses, combining a deep understanding of business strategies with pragmatic, Credo-based legal advice.

Prior to leading Medical Devices Legal group, Rob was the Worldwide Vice President -Law for the Global Orthopaedics Group, where he led the integration of the Synthes law department. In addition to overseeing the important relationship with the AO Foundation, Rob also traveled extensively, meeting with customers, healthcare systems and other key healthcare stakeholders.

Rob joined Johnson & Johnson in 2004 and served as Vice President-Law for the Ethicon Endo-Surgery (EES) franchise in Cincinnati until he assumed his role with the Global Orthopaedics Group. While supporting the EES franchise, Rob was instrumental in helping advance the growth of the franchise, including the launch of numerous innovative business models across the Endo-Mechanical, Obesity and Energy platforms. Rob was also a member of the EES Management Board and an executive sponsor on the EES Diversity & Inclusion Council.

Prior to joining Johnson & Johnson, Rob served as corporate counsel for General Electric (GE) Aircraft Engines. His primary responsibilities included serving as the general counsel of several business units and providing counsel on mergers, acquisitions, joint ventures and divestitures. He also was the lead lawyer on the integration of several significant acquisitions.

Prior to GE, Rob was in private legal practice at the Ohio law firm Katz Teller in the firm’s corporate and real estate department. Rob earned his Bachelor of Arts degree from The Ohio State University and a Juris Doctor degree from Boston College Law School.

Rob Fletcher, J.D.

GENERAL COUNSEL, PHARMACEUTICALS

JANE GRIFFITHS

GLOBAL HEAD, ACTELION

Jane Griffiths, Ph.D., is the Global Head of Actelion. She was named to this role in June 2017. Prior to this, Jane served as Company Group Chairman, Janssen Europe, Middle East and Africa (EMEA), providing strategic leadership, focusing on growth and building a sustainable business through people development and recruitment, and building trust and transparency both internally and externally.

In this role with Actelion, Jane will lead the successful integration of Actelion talent and capabilities into Janssen and Johnson & Johnson. She will chair the Actelion global leadership team, which will include Commercial, Medical Affairs, R&D, Supply Chain and all functional areas. With full, end-to-end P&L ownership, Jane will have responsibility for developing long-term strategic plans to maximize the growth of Actelion’s pulmonary arterial hypertension (PAH) medicines. She will play a key leadership role in the development and execution of Actelion’s portfolio and pipeline in partnership with R&D. And, she will lead the creation and delivery of commercial plans for the Actelion portfolio, ensuring profitable growth.

Under Jane’s leadership, Janssen EMEA achieved many noteworthy accomplishments, including the creation of Aspire, a program designed to drive the business to become a more outcomes-led organization; the establishment of the HEMAR and Real World Evidence teams; and the development and rollout of the customer-facing i-Connect system, improving metrics on activity and results.

Prior to leading Janssen EMEA, Jane was responsible for the EMEA Market Access unit. She has also served as International Vice President for Janssen-Cilag Northern Europe; Vice President, EMEA Biopharmaceuticals; and Managing Director, Ortho Biotech UK & Ireland.

An outspoken and passionate advocate for gender diversity, corporate social responsibility and sustainability, Jane has worked tirelessly to integrate these values throughout the organization. She will maintain her position as Chair of the Johnson & Johnson Corporate Citizenship Trust. Jane also believes strongly in improving the reputation of the pharmaceutical industry and has chaired the European Federation of Pharmaceutical Industries and Associations (EFPIA) executive committee, providing strong leadership on topics such as pricing, access and transparency of transfers of value to healthcare professionals.

Before her transition to general management, she held various positions of increasing responsibility in Sales, Marketing and R&D. Jane began her career with Johnson & Johnson in 1982 after earning her Ph.D. in Plant Biochemistry from the University of Aberystwyth, UK.

Jane Griffiths, Ph.D.

Global Head, Actelion

WILLIAM N. HAIT, M.D., Ph.D.

GLOBAL HEAD, RESEARCH & DEVELOPMENT

William N. Hait, M.D., Ph.D. is Global Head, Janssen Research & Development, LLC, the global research and development arm of Janssen, the pharmaceutical companies of Johnson & Johnson. In this role, he leads the global Research & Development (R&D) group in its mission to discover and develop innovative new medicines to address the world’s most serious unmet medical needs.

Bill joined the Johnson & Johnson Family of Companies in 2007 and assumed the role of Global Therapeutic Area Head, Oncology, in 2009.

Before that he was the founding Director of The (Rutgers) Cancer Institute of New Jersey, which he led to receive the National Cancer Institute’s highest designation of Comprehensive Cancer Center in 2002. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School.

After earning his B.A. from the University of Pennsylvania in Philadelphia, Bill received his M.D. and Ph.D. (Pharmacology) cum laude from the Medical College of Pennsylvania in Philadelphia, where he was elected to Alpha Omega Alpha. He joined the faculty of Yale University School of Medicine in New Haven, Connecticut in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. He is Board Certified in Internal Medicine and Medical Oncology.

Bill devoted his time to numerous advisory and editorial boards. He was Editor-in-Chief of Clinical Cancer Research and Associate Editor of Cancer Research, served as President of the American Association for Cancer Research from 2007–2008 and currently serves as Treasurer. He sits on various committees for the American Association of Cancer Research (Chair, Clinical Cancer Research Committee), the American Society of Clinical Oncology, the Association of American Cancer Institutes (Board of Directors), the National Cancer Institute Board of Scientific Advisors and is Chairman of the Executive Management Committee of Stand Up to Cancer. He currently is a member of the Rutgers Cancer Institute of New Jersey Director's Advisory Board, Board of External Advisors for the Dana Farber/Harvard Cancer Center, the Stand Up to Cancer Scientific Advisory Board, The Board of Directors of Research! America and the Vanderbilt University Biomedical Science Advisory Board.

Bill has received numerous awards and honors including the Burroughs Wellcome Award in Clinical Pharmacology, election to the American Society of Clinical Investigation, and in 2013 he was elected as a Fellow of the AACR Academy.

William N. Hait, M.D., Ph.D.

Global Head, Research & Development

KRISTEN MULHOLLAND

HEAD OF HUMAN RESOURCES, GLOBAL PHARMACEUTICALS GROUP AND EXTERNAL INNOVATION

Kristen Mulholland is the Head of Human Resources, Global Pharmaceuticals Group and External Innovation. In this role, she is responsible for the global talent, recruiting, diversity, compensation, benefits, employee relations, external innovation and all aspects of the human resources agenda for the pharmaceuticals group. She is a member of the Pharmaceuticals Group Operating Committee (GOC) and the Human Resources Executive Committee (HREC). Kristen assumed this role in July 2017.

Kristen has held several global HR Leadership positions since joining Johnson & Johnson in 2005 as Director, Human Resources, at Ethicon Endo-Surgery. As Vice President, Human Resources, she led innovative approaches for driving cultural change, talent management and engagement across the global Ethicon Endo-Surgery franchise. She was then named Vice President, Global Performance & Development, with responsibility for leading the enterprise strategic direction for enhancing employee performance and professional development. As Vice President, Human Resources, Global Pharmaceuticals Research & Development (R&D), Kristen advanced the Janssen R&D talent agenda, with a specific focus on enhancing the diversity of scientific talent and strengthening global, end-to-end Therapeutic Area capabilities as part of the Janssen 2020 strategy. As a member of the R&D Management Committee, Kristen led the development of an enterprise-wide approach for building and measuring innovation capabilities required of R&D leaders of the future.

Kristen more than 15 years of experience in consulting and the healthcare industry, having spent 10 years consulting with Ernst & Young as part of the Human Capital practice and 7 years with Eli Lilly and Company in various HR roles.

Kristen holds a Bachelor’s degree in political economics and German from Tulane University in New Orleans, Louisiana and a Master’s degree in organization development from Case Western Reserve in Cleveland, Ohio.

Kristen Mulholland

Head of Human Resources, Global Pharmaceuticals Group and External Innovation

GEORGIA N. PAPATHOMAS, Ph.D.

VICE PRESIDENT, CHIEF INFORMATION OFFICER, PHARMACEUTICALS

Georgia Papathomas, Ph.D. is Vice President, Chief Information Officer, Pharmaceuticals. In this position, Georgia’s goals include driving innovation in Information Technology (IT) and creating competitive advantage for the business through the use of technology, following changes in information flow across the healthcare industry, influencing changes in health IT, and building a strong and engaged global IT team. She assumed this position in January 2011.

Georgia is a member of the Pharmaceuticals Group Operating Committee (GOC). Prior to joining the company, she held the position of Senior Vice President, Chief Information Officer and Corporate Innovation Officer at Boehringer Ingelheim (BI) Pharmaceutical in Ridgefield, Connecticut, and served as a member of the BI-Pharmaceuticals Executive Leadership Team.

Georgia has worked with Pfizer as the Chief Technology Officer (CTO) for Europe, Middle East, and Africa (EMEA) and as Vice President, Global Customer Service Management; and with Lucent Technologies as Vice President-Global Professional Services/Network Solutions. She began her career in research at AT&T Bell Labs.

Among her many affiliations, Georgia is on the Board of the National Center for Women in Information, the Technology Board for Patient Care Primary Care Collaborative, and on the Board of the Madison YMCA. She is also a member of the North American Research Board, the New York Academy of Science, the Sigma Xi Research Honor Society, the Pharmaceutical Information Systems Association and the Executive Women’s Technology Forum, SWIFT.

Georgia received a Ph.D. in Engineering Science, a Master of Science in Engineering Mechanics, a Sloan Fellowship and Bachelor of Science, Civil Engineering all from Columbia University in New York City.

Georgia N. Papathomas, Ph.D.

Vice President, Chief Information Officer, Pharmaceuticals

AI HUA ONG

COMPANY GROUP CHAIRMAN, ASIA PACIFIC

Ai Hua Ong joined Johnson & Johnson more than 25 years with a desire to make a difference to the lives of patients. This passion continues today, in her role as Company Group Chairman for Janssen Asia Pacific, where she oversees operations that deliver pharmaceutical innovation in Australia, China, Hong Kong, India, Japan, Korea, New Zealand and Taiwan.

Based in her native Singapore, Ai Hua is known for her deep commitment to customers and patients, her strategic insights and global mindset. She is an active volunteer for charitable causes and a strong advocate for women in leadership.

In her previous role as President of One J&J Southeast Asia, Ai Hua was instrumental in the successful implementation of Johnson & Johnson’s first-ever one-company enterprise business model encompassing pharmaceuticals, consumer products and medical devices. She nurtured a business with strong growth and enhanced efficiency across 10 countries: Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam.

Ai Hua holds a Bachelor of Science in Microbiology and Biochemistry and an Master’s in Business Administration from the National University of Singapore. She began her career in 1991 as a product specialist with Johnson & Johnson Medical Singapore. Since then, she has held leadership roles across strategic marketing, sales management, and licensing and acquisition.

Ai Hua is a committed volunteer for charitable causes and acts as chair of J&J’s Asia Pacific Contributions Committee. She is also a council member of the Singapore Dover Park Hospice and a committee member of Beyond Social Services, an organization which supports children from disadvantaged families in Singapore.

Ai Hua Ong

Company Group Chairman
Asia Pacific

KRIS STERKENS

COMPANY GROUP CHAIRMAN,EUROPE, MIDDLE EAST, AND AFRICA

Since starting his career at Janssen in Belgium almost 30 years ago, Kris Sterkens has been part of many teams across EMEA, Asia Pacific, and the United States.

Moving on from his latest role as the Company Group Chairman of Janssen Asia Pacific, Kris was appointed Company Group Chairman of Europe, Middle East and Africa in June 2017. He was excited to return to his home country, Belgium, after spending over three years in Singapore since February 2014 for the Asia Pacific business.

Under Kris’ stewardship, Janssen Asia Pacific achieved notable milestones, including a return to growth in China and a successful business transformation in Japan. Kris also led teams in Korea, Australia, and New Zealand and successfully competed against new biosimilar entrant, in addition to achieving industry-leading growth in India. Throughout his career, Kris has demonstrated exceptional leadership and an ability to identify and develop talent. For instance, in Asia Pacific, he introduced Company Group Chairman’s Dialogue, a talent development programme which has engaged more than 100 emerging leaders.

Prior to that, Kris was leading the EMEA Strategy Organisation, alongside his role as Managing Director of the region’s Mid-Sized Markets. He was also the Managing Director for Janssen the Netherlands, the Benelux countries, and then Germany from 2007–2012.

Before his transition into General Management, Kris was Vice President, Finance and Chief Finance Officer (CFO) for Janssen EMEA.

Kris holds a Master’s degree in Applied Economics from the University of Antwerp, a Master's degree in Financial Management from the Flemish Institute of Management, and an MBA from the Solvay Business School in Brussels. Kris is fluent in Dutch, English, German, and French and has been a frequent speaker at business schools, medical and patient group events, and industry meetings.

Kris Sterkens

Company Group Chairman,
Europe, Middle East, and Africa

JENNIFER TAUBERT

COMPANY GROUP CHAIRMAN, JOHNSON & JOHNSON

Jennifer Taubert is Company Group Chairman, Johnson & Johnson, where she is responsible for the Janssen Pharmaceutical Companies throughout North America and Latin America. She is a member of the Corporation’s Management Committee and the Pharmaceuticals Group Operating Committee.

Jennifer has been a leader in shaping Janssen’s global strategy of transformational medical innovation, successfully commercializing critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, heart disease and diabetes, infectious diseases including HIV, and serious mental illness. She has built a portfolio that includes nine blockbuster therapies, and under her leadership Janssen has become one of the largest and fastest-growing pharmaceutical companies and a major catalyst of Johnson & Johnson’s growth. Jennifer is also recognized as a champion of diversity and inclusion, which she sees as critical to insight, innovation and business success.

In 2005, Jennifer joined Johnson & Johnson to lead global commercial strategy for Internal Medicine and Early Development for the Pharmaceuticals Group. Later, as President, Internal Medicine, she built a powerhouse new franchise in the cardiovascular and metabolism space, where Janssen is now a leader in both anticoagulation and diabetes. Prior to joining Johnson & Johnson, Jennifer spent 18 years in positions of increasing scope and responsibility at Merck and Allergan.

Fortune magazine named Jennifer to its 2016 “Most Powerful Women” list. In addition to her leadership at Johnson & Johnson, Jennifer serves on the Executive Committee of the Healthcare Leadership Council, a coalition of executives from all disciplines within healthcare. She is also a member of the National Academy of Medicine Leadership Consortium for Value and Science-Driven Healthcare, and at the global level, Jennifer represents Johnson & Johnson on the Executive Committee of the International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Jennifer received a Bachelor’s degree in Pharmacology from the University of California, Santa Barbara and a Master’s of Business Administration from the Anderson Graduate School of Management, University of California, Los Angeles.

Jennifer Taubert

Company Group Chairman
Johnson & Johnson

PATRICK VERHEYEN

GLOBAL HEAD, JANSSEN BUSINESS DEVELOPMENT

Patrick Verheyen is Global Head, Janssen Business Development. In this role, Patrick leads the business development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals for the Janssen Pharmaceutical Companies of Johnson & Johnson. Patrick assumed this role in April 2015.

Prior to this, Patrick helped design and launch Johnson & Johnson Innovation and was the Head of Johnson & Johnson Innovation, London. This Innovation strategy has delivered a robust early-stage portfolio and has helped earn Johnson & Johnson a reputation as a preferred partner with external innovators, entrepreneurs and academic institutions.

Patrick joined Johnson & Johnson in 1986 at Janssen Pharmaceuticals in Beerse, Belgium.  He has held several leadership roles within our Pharmaceuticals organization including Vice President, New Ventures, Pharmaceuticals, where he led an agile and diverse team who facilitated divestitures, established strategic collaborations and identified investments that provided Janssen with access to external innovation and early product flow.  Patrick also served as Vice President, M&A, where he facilitated strategic collaborations and acquisitions including Crucell, Elan and Cougar Biotechnology, and established spin-out companies, including Movetis.  Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large capital space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations, private equity groups and government institutions.

Before beginning his professional career, he studied bioengineering at the University of Leuven, Flanders, Belgium.

Patrick Verheyen

Global Head, Janssen Business Development

STEVE WOODING, M.D.

HEAD, GLOBAL COMMERCIAL STRATEGY ORGANIZATION

Steve Wooding, M. D., is Head, Global Commercial Strategy Organization (GCSO) and Market Access Organization, a position he assumed in June 2015. He is a member of the Pharmaceuticals Group Operating Committee (GOC), reporting to Joaquin Duato.

In this role, Steve leads the GCSO, with primary responsibility for the ongoing evolution and stewardship of Janssen 2020, our shared vision and global strategy to drive transformational medical innovation and position Janssen as a global pharmaceuticals leader. Steve and his team help identify and adapt to market challenges, develop new strategies for growth and in partnership with our research and development colleagues, seize opportunities to continue to transform the lives of patients around the world. Steve also has responsibility for Janssen Healthcare Innovation.

Most recently, Steve was Managing Director, Emerging Markets, Janssen EMEA (Europe, Middle East, Africa), with commercial responsibility for Central and Eastern Europe (CEE), Middle East, North and West Africa, Turkey, South Africa and Sub-Saharan Africa. Previously, as Vice President and Head of Market Access for EMEA, he built an integrated Market Access function, bringing together teams from the Commercial Strategy, Medical Affairs, Health Economics and Market Access, New Business Development, and Business Intelligence organizations to provide rapid and sustained patient access to our innovative new drugs. Prior to this, Steve was Vice President, Medical Affairs, Janssen EMEA. His strong vision for the future helped focus all Medical Affairs activities in Janssen EMEA and create a more cohesive and aligned function.

Previously, Steve served as Area Managing Director for Janssen United Kingdom (UK), Ireland and South Africa, and Managing Director for Australia and New Zealand. He joined Johnson & Johnson with Janssen UK in 1992, and held several positions of increasing responsibility within R&D, Medical Affairs and Commercial in the UK, Ireland, South Africa and Canada.

Steve earned a Bachelor of Science degree in Pharmacology and Bachelor of Medicine, Bachelor of Surgery degrees from St. Bartholomew’s Hospital in London. He is a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from Henley Management College, Oxfordshire, United Kingdom.

Steve Wooding, M.D.

Head, Global Commercial Strategy Organization